Cytomegalovirus (CMV) infection is the most common infectious complication following solid organ transplantation. Ganciclovir (GCV)-resistant CMV infection may be fatal, and is difficult to treat whilst avoiding allograft rejection. A 31-year-old woman received a second ABO-incompatible kidney transplant, from her father. Induction therapy consisted of basiliximab and rituximab followed by maintenance immunosuppression with tacrolimus, mycophenolate mofetil, and methylprednisolone. Her CMV serostatus was D + /R -at second transplant and she received prophylactic low-dose valganciclovir (VGCV).
D
+ /R -at second transplant and she received prophylactic low-dose valganciclovir (VGCV).
BK polyoma virus nephropathy (BKVN) developed 7 months after transplant concurrent
with CMV hepatitis and retinitis. VGCV was increased to a therapeutic dose combined with reduced immunosuppression with minimal methylprednisolone (2 mg/day) and everolimus (0.5 mg/day). However, pp65 antigenemia continued to increase for 6 weeks.
Her CMV was defined as ganciclovir (GCV)-resistant. Foscarnet was therefore administered and her CMV disease resolved within 2 weeks. Kidney allograft dysfunction 
Background
Cytomegalovirus (CMV) infection is the most common infectious disease following solid organ transplantation 1 , with significantly higher mortality in cases with primary infection.
Although the emergence of highly effective antiviral drugs such as ganciclovir (GCV) and its prodrug valganciclovir (VGCV) have dramatically reduced the incidence of severe CMV infection, GCV-resistant CMV infection can still be fatal, and is difficult to treat without reducing immunosuppression and thus risking allograft rejection. Here, we report a patient with primary GCV-resistant CMV infection following an ABO-incompatible second kidney transplant complicated by BK polyoma virus nephropathy (BKVN), who was successfully treated with foscarnet without acute allograft rejection. In addition, kidney allograft biopsy revealed crystal nephropathy suggesting foscarnet -induced tubulointerstitial toxicity, which resolved spontaneously after drug withdrawal.
Case Report
A 31-year-old woman (unknown original disease) underwent a second kidney transplant, with a kidney donated by her father. Her first transplant had been from her mother, but the allograft was lost after 10 years as a result of IgA nephropathy in the graft, complicated by VGCV was again increased to a therapeutic level and mycophenolate mofetil was replaced with everolimus, followed by a gradual reduction of other immunosuppression to methylprednisolone (2 mg/day) and everolimus (0.5 mg/day). However, her pp65
antigenemia continued to rise for 6 weeks up to 307 cells per 2×10 5 peripheral leukocytes, with high fever, liver dysfunction, and retinitis. There were no other organ symptoms related to CMV infection. Based on a diagnosis of GCV-resistant CMV, the patient was administered foscarnet, after which her antigenemia became negative and her CMV symptoms resolved within 2 weeks. CMV genotyping revealed an A594V mutation in the UL97 gene, which has been associated with an 8.3-fold increase in resistance to GCV 2 .
The patient's kidney allograft function worsened (sCr increase from 1.2 to 1.7 mg/dl) followed by hypocalcaemia, and allograft biopsy revealed tubulointerstitial damage with increased crystal deposition in the tubules, presumably caused by foscarnet, with no signs of rejection or BKVN (Fig. 2c, d , e). Immunostaining for CMV was negative (not shown), and the Banff classification was as follows: t0, i1, g0, v0, cg0, ci2, ct2, cv0, mm0, ptc0, c4d2, ti3, ah0, aah0, and ptcbm0. Allograft function recovered spontaneously after withdrawal of foscarnet. Repeated allograft biopsy revealed disappearance of crystal deposition in the tubules 17 months post-transplant ( Fig. 2f ; Banff classification: t0, i0, g0, v0, cg0, ci1, ct1, cv0, mm0, ptc0, c4d0, ti1, ah0, aah0, and ptcbm0). The patient had stable graft function (sCr, 1.28 mg/dl) with no signs of opportunistic infection or drug toxicity 18 months after kidney transplant. 
Discussion
The guanosine analogue GCV and its prodrug VGCV require phosphorylation, mediated by human CMV pUL97, for their antiviral activities 3 . Phosphorylated GCV is then incorporated into the DNA, resulting in reduction and termination of DNA replication 3, 4 .
Mutations in pUL97, a phosphotransferase encoded by the UL97 open reading frame and related to protein kinases, are the most common mutations leading to GCV resistance, responsible for increases in resistance up to 8-fold, compared with wild-type CMV 3 .
Many gene mutations have been identified as causes of GCV-resistance, of which UL97
A594V is the most frequent, resulting in an 8.3-fold increase in resistance to GCV 2 . In contrast, foscarnet is a pyrophosphate analogue that does not require phosphorylation for its antiviral activity. Foscarnet terminates replication by blocking the release of pyrophosphate by DNA polymerase, independent of UL97 5 .
Reported risk factors for GCV-resistance include an insufficient dose of GCV/VGCV and longer duration of treatment or prophylaxis 6 . However, the appropriate haematological events such as neutropenia 6 . Prolonged prophylaxis can also cause late-onset CMV infection after cessation of prophylaxis. Accordingly, the Transplantation Society International CMV Consensus Group suggested a hybrid approach involving preemptive treatment followed by secondary prophylaxis, or prophylaxis followed by preemptive therapy 7 . In the current case, prolonged and insufficient administration of prophylactic VGCV may have resulted in the observed GCV-resistant CMV infection.
Although no controlled studies have been performed, conversion to foscarnet is recommended in the updated guidelines for CMV management, especially in patients who demonstrate high resistance to GCV, such as the current case 7 . Evidence for the efficacy of combination therapy of GCV and foscarnet is limited 7 .
Nephrotoxicity caused by antiviral drugs is not rare, but is hard to confirm by renal needle biopsy, especially in patients with haemorrhagic events. Many kinds of antiviral drugs can cause nephrotoxicity via the deposition of calcium crystals 8 . Calcium crystal deposition in the glomerular capillaries, rather than in the tubules, is more specific to foscarnet-induced nephrotoxicity 8 . Kidney functional and pathological changes are reversible as long as the fibrotic changes are not severe and the patient receives adequate hydration 9 . In our case, allograft rejection, recurrence of BKVN, CMV infection, and calcineurin inhibitor nephrotoxicity were taken into consideration 9 months after transplant. Increased crystal deposition in the tubules, but not in the glomerular capillaries, revealed by allograft biopsy, together with the results of other laboratory tests and her subsequent clinical course, were suggestive of foscarnet-induced nephrotoxicity. In addition, repeated biopsy 17 months after transplant showed a marked decrease of calcium deposition with mild fibrotic changes.
In conclusion, we experienced a patient with primary GCV-resistant CMV infection following ABO-incompatible kidney transplant complicated by BKVN, who was successfully treated with foscarnet together with reduced immunosuppression, without the development of acute allograft rejection. Allograft biopsy also confirmed antiviral-drug-induced nephrotoxicity pathologically and recorded its improvement after foscarnet cessation. This case highlights the need to establish the optimal strategy for preventing and/or treating severe infection in CMV-seronegative recipients whilst avoiding the acquisition of GCV-resistance gene mutations. 
